

## ARTMENT OF COMMERCE UNITED STATES D **Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

APPLICATION NO. **FILING DATE** FIRST NAMED INVENTOR ATTORNEY DOCKET NO. G

09/214,701

THOMAS G WISEMAN

MORRISON & FOERSTER

WASHINGTON DC 20006-1888

09/30/99

LOWELL

406462000200

HM12/1214

2000 PENNSYLVANIA AVENUE NW

**EXAMINER** 

PARKIN, J

**ART UNIT** 

PAPER NUMBER

1648

**DATE MAILED:** 

12/14/00

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 

# Office Action Summary

Application No. 09/214,701

Lowell, G., et al.

Examiner

Jeffrey S. Parkin, Ph.D.

Group Art Unit 1648



X Responsive to communication(s) filed on 1 Apr 1999	
This action is <b>FINAL</b> .	
Since this application is in condition for allowance except fo in accordance with the practice under <i>Ex parte Quayle</i> , 193	
A shortened statutory period for response to this action is set to is longer, from the mailing date of this communication. Failure application to become abandoned. (35 U.S.C. § 133). Extensi 37 CFR 1.136(a).	to respond within the period for response will cause the
Disposition of Claims	
X Claim(s) <u>1-32</u>	is/are pending in the application.
Of the above, claim(s)	is/are withdrawn from consideration.
Claim(s)	
Claim(s)	
Claim(s)	
Application Papers	a Paviaus PTO 049
See the attached Notice of Draftsperson's Patent Drawing	
The drawing(s) filed on is/are object	
The proposed drawing correction, filed on	is _approved _disapproved.
The specification is objected to by the Examiner.	
The oath or declaration is objected to by the Examiner.	
Priority under 35 U.S.C. § 119	
Acknowledgement is made of a claim for foreign priority	under 35 U.S.C. § 119(a)-(d).
All Some* None of the CERTIFIED copies o	if the priority documents have been
received.	
☐ received in Application No. (Series Code/Serial Nur	mber)
$\square$ received in this national stage application from the	International Bureau (PCT Rule 17.2(a)).
*Certified copies not received:	
Acknowledgement is made of a claim for domestic priorit	ty under 35 U.S.C. § 119(e).
Attachment(s)	
Notice of References Cited, PTO-892	
[] Information Disclosure Statement(s), PTO-1449, Paper No.	o(s)
Interview Summary, PTO-413	
Notice of Draftsperson's Patent Drawing Review, PTO-94	18
Notice of Informal Patent Application, PTO-152	
SEE OFFICE ACTION ON 1	THE FOLLOWING PAGES

Serial No.: 09/214,701 Docket No.: 406462000200

Applicants: Lowell, G., et al. Filing Date: 09/30/99

#### Restriction Requirement

## Fax Response Pilot for

#### Written Restriction Requirements

1. In an effort to enhance communication with our customers and reduce processing time, Group 1640 is running a Fax Response Pilot for Written Restriction Requirements. A dedicated Fax machine is in place to receive your responses. The Fax number is (703) 305-3704. A Fax cover sheet is attached to this Office Action for your convenience. We encourage your participation in this Pilot If you have any questions or suggestions please contact Hutzell, Supervisory Patent Examiner, Paula Paula. Hutzell@uspto.gov or 703-308-4310. Thank you in advance for allowing us to enhance our customer service. Please limit the use of this dedicated Fax number to responses to Written Restrictions.

5

10

15

20

25

30

#### 35 U.S.C. § 371

- 2. This application was filed under 35 U.S.C. § 371 and is subject to unity of invention practice pursuant to 35 U.S.C. § 121 and 372. This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In accordance with 37 C.F.R. § 1.499, applicants are required, in response to this action, to elect a single invention to which the claims must be restricted.
  - a. Group I, claims 1-18, drawn to vaccine compositions comprising an antigen the comprises endogenous or exogenous hydrophobic sequences.
  - b. Group II) claims 19-32, drawn to processes for inducing neutralizing antibody responses in a subject through the administration of a vaccine composition comprising an antigen the comprises endogenous or exogenous hydrophobic sequences.

Serial No.: 09/214,701 Applicants: Lowell, G., et al.

The inventions listed as Groups I and II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the broadly claimed invention fails to provide a contribution over the prior art since the claimed vaccine compositions and methods of using said compositions already exist (e.g., see the International Search and Preliminary Examination Reports dated 03 March, 1998, and 17 September, 1998, respectively, both of which cite a number of references that render the claimed invention obvious).

5

10

15

20

25

3. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).

## Correspondence

- 4. The Art Unit location of your application in the Patent and Trademark Office has changed. To facilitate the correlation of related papers and documents for this application, all future correspondence should be directed to art unit 1648.
- 5. Correspondence related to this application may be submitted to Group 1600 by facsimile transmission. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). Official communications should be directed toward one of the following Group 1600 fax numbers: (703) 308-4242 or (703) 305-3014. Informal communications may be submitted directly to the Examiner through the following fax number: (703) 308-4426. Applicants are encouraged to notify the

Serial No.: 09/214,701 Applicants: Lowell, G., et al.

Examiner prior to the submission of such documents to facilitate their expeditious processing and entry.

6. Any inquiry concerning this communication should be directed to Jeffrey S. Parkin, Ph.D., whose telephone number is (703) 308-2227. The examiner can normally be reached Monday through Thursday from 8:30 AM to 6:00 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner are unsuccessful, the examiner's supervisors, James Housel or Laurie Scheiner, can be reached at (703) 308-4027 or (703) 308-1122, respectively. Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (703) 308-0196.

Respectfully,

5

10

Jeffrey S. Parkin, Ph.D.

Patent Examiner Art Unit 1648

13 December, 2000